Tom Dudding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tom Dudding has a total of 529 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Allemani
Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , Keppel Street, London, WC1E 7HT
17 shared publications - Emily A.M. Black
University of Bristol Dental School, Bristol, United Kingdom
17 shared publications - Mark Gormley
MRC Integrative Epidemiology Unit, University of Bristol
16 shared publications - Nicholas John Timpson
University of Bristol
16 shared publications - Simon Haworth
Department of Odontology, Umeå University
13 shared publications - Shama Virani
Genomic Epidemiology Branch, International Agency for Research on Cancer , Lyon
11 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- p. 1-12
Patients’ concerns at 10 years following head and neck cancer treatment
Purpose: Patients experience profound functional, psychological and social impacts following head and neck cancer (HNC) diagnosis and treatment. These impacts can generate concerns that patients wish to discuss during post-treatment consultations. Although these concerns have been reported in the first five years after diagnosis, there is little information regarding the concerns reported by survivors in the longer -term. The aim of this cross-sectional study was to report patient concerns 10-years following the diagnosis and treatment of oral cavity, oropharyngeal and laryngeal squamous cell carcinoma. Methods: We conducted a descriptive analysis of 10-year follow-up data from the Head and Neck 5000 (HN5000) cohort summarising Patient Concerns Inventory (PCI) responses across clinical subgroups. Results: Of the 5,421 participants, 2,513 were alive at 10-years; 1,035 returned the questionnaire, with 661 selecting at least one PCI concern or healthcare professional. The most frequent concerns were dry mouth (43%), swallowing (42%), fear of recurrence (33%), dental health (32%), and chewing (29%). These concerns were present across early and late-stage oral, oropharyngeal, laryngeal sites, though subtle differences were observed. Although all 18 multi-professionals were selected, the two most frequent were dentist (36%) and Speech and Language Therapy (23%). Conclusion: A broad range of patient-prioritised concerns were reported by HNC survivors 10 years following treatment. As survival rates in HNC improve there will be an increasing number of patients living with the long-term consequences of cancer and its treatment. Thus, healthcare resources and support need to be focused on addressing those that concern patients most.
- 31 October 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- p. 1-12
Open AccessPatients’ concerns at 10 years following head and neck cancer treatment
Purpose: Patients experience profound functional, psychological and social impacts following head and neck cancer (HNC) diagnosis and treatment. These impacts can generate concerns that patients wish to discuss during post-treatment consultations. Although these concerns have been reported in the first five years after diagnosis, there is little information regarding the concerns reported by survivors in the longer -term. The aim of this cross-sectional study was to report patient concerns 10-years following the diagnosis and treatment of oral cavity, oropharyngeal and laryngeal squamous cell carcinoma. Methods: We conducted a descriptive analysis of 10-year follow-up data from the Head and Neck 5000 (HN5000) cohort summarising Patient Concerns Inventory (PCI) responses across clinical subgroups. Results: Of the 5,421 participants, 2,513 were alive at 10-years; 1,035 returned the questionnaire, with 661 selecting at least one PCI concern or healthcare professional. The most frequent concerns were dry mouth (43%), swallowing (42%), fear of recurrence (33%), dental health (32%), and chewing (29%). These concerns were present across early and late-stage oral, oropharyngeal, laryngeal sites, though subtle differences were observed. Although all 18 multi-professionals were selected, the two most frequent were dentist (36%) and Speech and Language Therapy (23%). Conclusion: A broad range of patient-prioritised concerns were reported by HNC survivors 10 years following treatment. As survival rates in HNC improve there will be an increasing number of patients living with the long-term consequences of cancer and its treatment. Thus, healthcare resources and support need to be focused on addressing those that concern patients most.
- Open Access
- 7 October 2026
- Published by CERN in Open Research Europe
The HEADSpAcE Data Center: An international data and biospecimen resource for head and neck cancer translational research
Head and neck cancer (HNC) comprises a heterogeneous group of malignancies with substantial variation in incidence, risk factors, and outcomes across populations. Existing studies are often limited by regional scope or lack integration of epidemiological, clinical, and molecular data, restricting the ability to investigate determinants of disease risk, diagnosis, and survival on a global scale. The HEADSpAcE Data Center was established to address these gaps by integrating data and biospecimens from multiple international studies and consortia across North America, South America, Europe, and the Eastern Mediterranean under a shared governance framework that defines future access and use of the resource as has been agreed upon by participating principal investigators. The resource currently includes over 27,000 participants from 18 countries, encompassing detailed demographic, lifestyle, clinical, and follow-up/outcome data, with linked biospecimens and molecular profiling. Cancer cases included are from the oral cavity, oropharynx, larynx, and hypopharynx. Participant recruitment spans the periods from 1991 to 2025. The Data Center incorporates standardized variables on risk factors (e.g., tobacco, alcohol, HPV), tumor characteristics, and disease outcomes, as well as detailed information on diagnostic pathways from the most recent recruitment. Molecular data include HPV-related assays, germline genotyping, targeted and/or genome-wide tumor sequencing, and transcriptomic tumor profiling. Biospecimens include blood-derived samples, oral samples and tumor tissues, with availability varying by region and study. By combining multi-level data within a harmonized framework, the HEADSpAcE Data Center provides a platform for large-scale analyses of HNC risk, diagnosis, and survival across populations. The resource is open to new centers wishing to contribute data and biospecimens to expand representation across regions and populations. Data access and contribution procedures are available at www.headspace.iarc.who.int.
- 7 October 2026
- Published by CERN in Open Research Europe
Open AccessThe HEADSpAcE Data Center: An international data and biospecimen resource for head and neck cancer translational research
Head and neck cancer (HNC) comprises a heterogeneous group of malignancies with substantial variation in incidence, risk factors, and outcomes across populations. Existing studies are often limited by regional scope or lack integration of epidemiological, clinical, and molecular data, restricting the ability to investigate determinants of disease risk, diagnosis, and survival on a global scale. The HEADSpAcE Data Center was established to address these gaps by integrating data and biospecimens from multiple international studies and consortia across North America, South America, Europe, and the Eastern Mediterranean under a shared governance framework that defines future access and use of the resource as has been agreed upon by participating principal investigators. The resource currently includes over 27,000 participants from 18 countries, encompassing detailed demographic, lifestyle, clinical, and follow-up/outcome data, with linked biospecimens and molecular profiling. Cancer cases included are from the oral cavity, oropharynx, larynx, and hypopharynx. Participant recruitment spans the periods from 1991 to 2025. The Data Center incorporates standardized variables on risk factors (e.g., tobacco, alcohol, HPV), tumor characteristics, and disease outcomes, as well as detailed information on diagnostic pathways from the most recent recruitment. Molecular data include HPV-related assays, germline genotyping, targeted and/or genome-wide tumor sequencing, and transcriptomic tumor profiling. Biospecimens include blood-derived samples, oral samples and tumor tissues, with availability varying by region and study. By combining multi-level data within a harmonized framework, the HEADSpAcE Data Center provides a platform for large-scale analyses of HNC risk, diagnosis, and survival across populations. The resource is open to new centers wishing to contribute data and biospecimens to expand representation across regions and populations. Data access and contribution procedures are available at www.headspace.iarc.who.int.
- Open Access
- 13 August 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Somatic alterations in TP53 , PIK3CA , and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors
Background: Tobacco, alcohol, and human papillomavirus (HPV) are major risk factors for oral cavity and oropharyngeal cancers, yet their specific contributions to the tumor molecular landscape remain incompletely understood. Methods: We analyzed somatic alterations in 1086 tumors (606 oral cavity cancers and 480 oropharyngeal cancers, including 287 HPV-positive oropharyngeal cancers) profiled with a 1109-gene panel and evaluated their associations with exposures. Results: PIK3CA alterations were widespread but context specific: HPV-positive oropharyngeal cancers featured APOBEC-driven mutations and co-occurrence of FGFR3 mutations in a subset of cases, while HPV-negative oropharyngeal cancers and oral cavity cancers were marked by 3q26/28 (PIK3CA/TP63/SOX2) amplifications. TP53 was the most frequently mutated gene in HPV-negative tumors, with strong enrichment among smokers in HPV-negative oropharyngeal cancers, whereas TP53 mutation frequencies in oral cavity cancers were consistently high, regardless of smoking status. CCND1 amplifications were largely restricted to HPV-negative tumors and were most frequent in individuals reporting combined tobacco and alcohol use. This combined effect was replicated in The Cancer Genome Atlas oral cavity cancer–oropharyngeal cancer cohort and mirrored at the transcriptomic level, where CCND1 messenger RNA expression was highest in dual tobacco-alcohol users. Within oral cavity cancers, characterization of 1 of the largest cohorts of tumors from never smoker–never drinkers to date (n = 100) showed that patients were more likely to be female and to exhibit enrichment for FAT1 and CASP8 mutations compared with tumors from ever smoker–ever drinkers (n = 353). Conclusions: Together, these findings define distinct, exposure-driven patterns of somatic alterations by subsite and HPV status and provide a molecular framework that may inform etiological-based risk stratification in head and neck cancer.
- 13 August 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessSomatic alterations in TP53 , PIK3CA , and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors
Background: Tobacco, alcohol, and human papillomavirus (HPV) are major risk factors for oral cavity and oropharyngeal cancers, yet their specific contributions to the tumor molecular landscape remain incompletely understood. Methods: We analyzed somatic alterations in 1086 tumors (606 oral cavity cancers and 480 oropharyngeal cancers, including 287 HPV-positive oropharyngeal cancers) profiled with a 1109-gene panel and evaluated their associations with exposures. Results: PIK3CA alterations were widespread but context specific: HPV-positive oropharyngeal cancers featured APOBEC-driven mutations and co-occurrence of FGFR3 mutations in a subset of cases, while HPV-negative oropharyngeal cancers and oral cavity cancers were marked by 3q26/28 (PIK3CA/TP63/SOX2) amplifications. TP53 was the most frequently mutated gene in HPV-negative tumors, with strong enrichment among smokers in HPV-negative oropharyngeal cancers, whereas TP53 mutation frequencies in oral cavity cancers were consistently high, regardless of smoking status. CCND1 amplifications were largely restricted to HPV-negative tumors and were most frequent in individuals reporting combined tobacco and alcohol use. This combined effect was replicated in The Cancer Genome Atlas oral cavity cancer–oropharyngeal cancer cohort and mirrored at the transcriptomic level, where CCND1 messenger RNA expression was highest in dual tobacco-alcohol users. Within oral cavity cancers, characterization of 1 of the largest cohorts of tumors from never smoker–never drinkers to date (n = 100) showed that patients were more likely to be female and to exhibit enrichment for FAT1 and CASP8 mutations compared with tumors from ever smoker–ever drinkers (n = 353). Conclusions: Together, these findings define distinct, exposure-driven patterns of somatic alterations by subsite and HPV status and provide a molecular framework that may inform etiological-based risk stratification in head and neck cancer.
- 2 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (9) , 1610-1619
Genetically proxied inhibition of cholesterol-lowering drug targets and survival in HPV-positive and non-HPV driven head and neck cancer: a multicentre MR study
Background: Cholesterol pathways may influence head and neck squamous cell carcinoma (HNSCC) progression, but evidence on prognosis is inconsistent. We used Mendelian randomization (MR) to test whether genetically proxied inhibition of major LDL-C–lowering drug targets and circulating lipid traits affects overall survival (OS) in HPV-positive and non-HPV driven HNSCC. Methods: We proxied lifelong LDL-C lowering using 55 cis-acting SNPs in HMGCR, NPC1L1, PCSK9, and LDLR from the updated 2021 Global Lipids Genetics Consortium, and instrumented circulating lipid traits. Two-sample MR estimated effects on OS in 4,869 multi-centre HNSCC cases (1,291 HPV-positive; 3,578 non-HPV driven) using minimally adjusted Cox models. Sensitivity analyses additionally adjusted for tumour stage and treatment, assessed collider bias using an external HNSCC incidence GWAS, and examined between-centre heterogeneity and colocalization. Results: Using the updated GLGC 2021 instruments, genetically proxied HMGCR inhibition showed a directionally protective but non-significant association with OS in HPV-positive oropharyngeal HNSCC in the primary analysis (IVW HR=0.19, 95% CI 0.03–1.18; P=0.08), with directionally concordant weighted median results. No corresponding protective association was observed for HMGCR in non-HPV-driven disease (IVW HR=1.68, 95% CI 0.78–3.63; P=0.19). No clear evidence of association was observed for NPC1L1, PCSK9, LDLR, or circulating lipid traits in either HPV stratum. Colocalization did not support a shared causal variant. Conclusions: These analyses provide suggestive evidence that genetically proxied HMGCR inhibition may influence survival in HPV-positive oropharyngeal HNSCC. Impact: HMGCR-related pathways may be relevant to prognosis in HPV-positive oropharyngeal HNSCC, whereas clear survival effects of other cholesterol-lowering targets were not supported.
- 2 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (9) , 1610-1619
Genetically proxied inhibition of cholesterol-lowering drug targets and survival in HPV-positive and non-HPV driven head and neck cancer: a multicentre MR study
Background: Cholesterol pathways may influence head and neck squamous cell carcinoma (HNSCC) progression, but evidence on prognosis is inconsistent. We used Mendelian randomization (MR) to test whether genetically proxied inhibition of major LDL-C–lowering drug targets and circulating lipid traits affects overall survival (OS) in HPV-positive and non-HPV driven HNSCC. Methods: We proxied lifelong LDL-C lowering using 55 cis-acting SNPs in HMGCR, NPC1L1, PCSK9, and LDLR from the updated 2021 Global Lipids Genetics Consortium, and instrumented circulating lipid traits. Two-sample MR estimated effects on OS in 4,869 multi-centre HNSCC cases (1,291 HPV-positive; 3,578 non-HPV driven) using minimally adjusted Cox models. Sensitivity analyses additionally adjusted for tumour stage and treatment, assessed collider bias using an external HNSCC incidence GWAS, and examined between-centre heterogeneity and colocalization. Results: Using the updated GLGC 2021 instruments, genetically proxied HMGCR inhibition showed a directionally protective but non-significant association with OS in HPV-positive oropharyngeal HNSCC in the primary analysis (IVW HR=0.19, 95% CI 0.03–1.18; P=0.08), with directionally concordant weighted median results. No corresponding protective association was observed for HMGCR in non-HPV-driven disease (IVW HR=1.68, 95% CI 0.78–3.63; P=0.19). No clear evidence of association was observed for NPC1L1, PCSK9, LDLR, or circulating lipid traits in either HPV stratum. Colocalization did not support a shared causal variant. Conclusions: These analyses provide suggestive evidence that genetically proxied HMGCR inhibition may influence survival in HPV-positive oropharyngeal HNSCC. Impact: HMGCR-related pathways may be relevant to prognosis in HPV-positive oropharyngeal HNSCC, whereas clear survival effects of other cholesterol-lowering targets were not supported.
- Open Access
- 11 October 2025
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 34 (23) , 1934-1950
Genetic heterogeneity and homogeneity among orofacial cleft subtypes: genome-wide association studies in the cleft collective
Several genome wide association studies (GWASs) of orofacial cleft have been conducted. However only a few such studies to date have combined all cleft cases, focused on subtypes other than non-syndromic cleft lip with/without cleft palate, or investigated subtype heterogeneity. We conducted a GWAS of orofacial clefts within 2268 cases from the Cleft Collective and 7913 population-based controls; we performed analyses of all orofacial clefts, plus 7 subgroups. We replicated our findings in a meta-analysis of independent samples and investigated patterns of correlation across subgroups. We identified 27 regions at genome-wide significance, 8 of which were novel. We also conducted the first GWAS of Pierre Robin Sequence, despite the small sample size (n cases = 237), we found one genome wide significant SNP (P < 5 × 10−8), and another 21 suggestive associations (P < 10−5). Novel loci include those mapping to LHX8 and TSBP1 (combined clefts), ARHGEF18 and ARHGEF19 (cleft lip with/without palate), FBN2 (cleft lip only), SLC35B3 (cleft palate only), CASC20 (Pierre Robin Sequence) and CHRM2 (non-syndromic cleft palate only). Several novel hits were in regions previously associated with facial morphology in GWAS or were in regions involved in key developmental processes, including neural crest cell migration and craniofacial development. We identified genetic loci with similar effects across all subgroups and some loci which were subtype specific, we also identified 3 loci with opposing effects on cleft lip and Pierre Robin sequence. Our findings highlight the merit of including all orofacial cleft subtypes in GWAS studies and investigating heterogeneity of effects across subtypes.
- 11 October 2025
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 34 (23) , 1934-1950
Open AccessGenetic heterogeneity and homogeneity among orofacial cleft subtypes: genome-wide association studies in the cleft collective
Several genome wide association studies (GWASs) of orofacial cleft have been conducted. However only a few such studies to date have combined all cleft cases, focused on subtypes other than non-syndromic cleft lip with/without cleft palate, or investigated subtype heterogeneity. We conducted a GWAS of orofacial clefts within 2268 cases from the Cleft Collective and 7913 population-based controls; we performed analyses of all orofacial clefts, plus 7 subgroups. We replicated our findings in a meta-analysis of independent samples and investigated patterns of correlation across subgroups. We identified 27 regions at genome-wide significance, 8 of which were novel. We also conducted the first GWAS of Pierre Robin Sequence, despite the small sample size (n cases = 237), we found one genome wide significant SNP (P < 5 × 10−8), and another 21 suggestive associations (P < 10−5). Novel loci include those mapping to LHX8 and TSBP1 (combined clefts), ARHGEF18 and ARHGEF19 (cleft lip with/without palate), FBN2 (cleft lip only), SLC35B3 (cleft palate only), CASC20 (Pierre Robin Sequence) and CHRM2 (non-syndromic cleft palate only). Several novel hits were in regions previously associated with facial morphology in GWAS or were in regions involved in key developmental processes, including neural crest cell migration and craniofacial development. We identified genetic loci with similar effects across all subgroups and some loci which were subtype specific, we also identified 3 loci with opposing effects on cleft lip and Pierre Robin sequence. Our findings highlight the merit of including all orofacial cleft subtypes in GWAS studies and investigating heterogeneity of effects across subtypes.
- Open Access
- 9 October 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Reassessing the link between adiposity and head and neck cancer: a Mendelian randomization study
Background: Adiposity has been associated with an increased risk of head and neck cancer (HNC). Although body mass index (BMI) has been inversely associated with HNC risk among smokers, this is likely due to confounding. Previous Mendelian randomization (MR) studies could not fully discount causality between adiposity and HNC. Hence, we aimed to revisit this using the largest genome-wide association study (GWAS) of HNC available, which has more granular data on HNC subsites. Methods: We assessed the genetically predicted effects of BMI (N=806,834), waist-to-hip ratio (WHR; N=697,734) and waist circumference (N=462,166) on the risk of HNC (N=12,264 cases) and its subsites using a two-sample MR framework. We used inverse variance weighted (IVW) MR and multiple sensitivity analyses, including multivariable MR (MVMR), to explore the direct effects of the adiposity measures on HNC, while accounting for smoking behaviour (a well-known HNC risk factor). Results: In univariable MR, higher genetically predicted BMI increased the risk of overall HNC (IVW OR = 1.17 per 1-SD higher BMI, 95% CI 1.02–1.34). However, the IVW effect was attenuated when smoking was included in the MVMR model (OR accounting for comprehensive smoking index = 0.96 per 1-SD higher BMI, 95% CI 0.80–1.15). Furthermore, we did not find a link between genetically predicted WHR (IVW OR = 1.05 per 1-SD higher WHR, 95% CI 0.89–1.24) or waist circumference and HNC risk (IVW OR = 1.01 per 1-SD higher waist circumference, 95% CI 0.85–1.21). Conclusions: Our findings suggest that adiposity does not play a major role in HNC risk. Funding: FMB was supported by a Wellcome Trust PhD studentship in Molecular, Genetic and Lifecourse Epidemiology (224982/Z/22/Z). RCR was supported by a Cancer Research UK grant (C18281/A29019). MCB is supported by a University of Bristol Vice Chancellor’s Fellowship, the British Heart Foundation (AA/18/1/34219) and the UK Medical Research Council (MC_UU_00032/5). GDS works within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00032/1). CLR was supported by the Medical Research Council (MC_UU_00011/5) and by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). SV was funded by an EU Horizon 2020 grant (agreement number 825771) and NIDCR National Institutes of Dental and Craniofacial Health (R03DE030257). JK works in a unit that receives support from the University of Bristol, a Cancer Research UK grant (C18281/A29019) and the UK Medical Research Council (grant number: MC_UU_00032/7).
- 9 October 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessReassessing the link between adiposity and head and neck cancer: a Mendelian randomization study
Background: Adiposity has been associated with an increased risk of head and neck cancer (HNC). Although body mass index (BMI) has been inversely associated with HNC risk among smokers, this is likely due to confounding. Previous Mendelian randomization (MR) studies could not fully discount causality between adiposity and HNC. Hence, we aimed to revisit this using the largest genome-wide association study (GWAS) of HNC available, which has more granular data on HNC subsites. Methods: We assessed the genetically predicted effects of BMI (N=806,834), waist-to-hip ratio (WHR; N=697,734) and waist circumference (N=462,166) on the risk of HNC (N=12,264 cases) and its subsites using a two-sample MR framework. We used inverse variance weighted (IVW) MR and multiple sensitivity analyses, including multivariable MR (MVMR), to explore the direct effects of the adiposity measures on HNC, while accounting for smoking behaviour (a well-known HNC risk factor). Results: In univariable MR, higher genetically predicted BMI increased the risk of overall HNC (IVW OR = 1.17 per 1-SD higher BMI, 95% CI 1.02–1.34). However, the IVW effect was attenuated when smoking was included in the MVMR model (OR accounting for comprehensive smoking index = 0.96 per 1-SD higher BMI, 95% CI 0.80–1.15). Furthermore, we did not find a link between genetically predicted WHR (IVW OR = 1.05 per 1-SD higher WHR, 95% CI 0.89–1.24) or waist circumference and HNC risk (IVW OR = 1.01 per 1-SD higher waist circumference, 95% CI 0.85–1.21). Conclusions: Our findings suggest that adiposity does not play a major role in HNC risk. Funding: FMB was supported by a Wellcome Trust PhD studentship in Molecular, Genetic and Lifecourse Epidemiology (224982/Z/22/Z). RCR was supported by a Cancer Research UK grant (C18281/A29019). MCB is supported by a University of Bristol Vice Chancellor’s Fellowship, the British Heart Foundation (AA/18/1/34219) and the UK Medical Research Council (MC_UU_00032/5). GDS works within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00032/1). CLR was supported by the Medical Research Council (MC_UU_00011/5) and by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). SV was funded by an EU Horizon 2020 grant (agreement number 825771) and NIDCR National Institutes of Dental and Craniofacial Health (R03DE030257). JK works in a unit that receives support from the University of Bristol, a Cancer Research UK grant (C18281/A29019) and the UK Medical Research Council (grant number: MC_UU_00032/7).
- Open Access
- 2 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites
Head and neck squamous cell carcinoma (HNSCC) includes diverse cancers arising in the oral cavity, oropharynx, and larynx, with the main risk factors being environmental exposures such as tobacco, alcohol, and human papillomavirus (HPV) infection. The genetic factors contributing to susceptibility across different populations and tumour subsites remain incompletely understood. Here we show, through a genome-wide association and fine mapping study of over 19,000 HNSCC cases and 38,000 controls from multiple ancestries, 18 genetic risk variants and 11 signals from fine mapping of the human leukocyte antigen (HLA) region, all previously unreported. rs78378222, a regulatory variant for TP53 is associated with a 40% reduction in overall HNSCC risk. We also identify gene-environment interactions, with BRCA2 and ADH1B variants showing effects modified by smoking and alcohol use. Subsite-specific analysis of the HLA region reveals distinct immune-related associations across HPV-positive and HPV-negative tumours. These findings refine the genetic architecture of HNSCC and highlight mechanisms linking inherited variation, immunity, and environmental exposures.
- 2 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessCross-ancestral GWAS identifies 29 variants across head and neck cancer subsites
Head and neck squamous cell carcinoma (HNSCC) includes diverse cancers arising in the oral cavity, oropharynx, and larynx, with the main risk factors being environmental exposures such as tobacco, alcohol, and human papillomavirus (HPV) infection. The genetic factors contributing to susceptibility across different populations and tumour subsites remain incompletely understood. Here we show, through a genome-wide association and fine mapping study of over 19,000 HNSCC cases and 38,000 controls from multiple ancestries, 18 genetic risk variants and 11 signals from fine mapping of the human leukocyte antigen (HLA) region, all previously unreported. rs78378222, a regulatory variant for TP53 is associated with a 40% reduction in overall HNSCC risk. We also identify gene-environment interactions, with BRCA2 and ADH1B variants showing effects modified by smoking and alcohol use. Subsite-specific analysis of the HLA region reveals distinct immune-related associations across HPV-positive and HPV-negative tumours. These findings refine the genetic architecture of HNSCC and highlight mechanisms linking inherited variation, immunity, and environmental exposures.
- Open Access
- 13 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1836-1847
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention
Background: The role of lipid-perturbing medications in cancer risk is unclear. Methods: We employed cis-Mendelian randomization and colocalization to evaluate the role of 5 lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, and PCSK9) in risk of 5 cancers (breast, colorectal, head and neck, ovarian, and prostate). We triangulated findings using pre-diagnostic protein measures in prospective analyses in EPIC (977 colorectal cancer cases, 4080 sub-cohort members) and the UK Biobank (860 colorectal cancer cases, 50 177 controls). To gain mechanistic insight into the role of ANGPTL4 in carcinogenesis, we examined the impact of the ANGPTL4 p. E40K loss-of-function variant on differential gene expression in normal colon tissue in BarcUVa-Seq. Finally, we evaluated the association of colon tumor ANGPTL4 expression with cancer-specific mortality in TCGA. Results: In analysis of 78 473 cases and 107 143 controls, genetically proxied circulating ANGPTL4 inhibition was associated with reduced colorectal cancer risk (ORSD decrease = 0.76, 95% confidence interval [CI] = 0.66 to 0.89, P = 5.52 × 10−4, PPcolocalization = 0.83). This association was replicated using pre-diagnostic circulating ANGPTL4 concentrations in EPIC (hazard ratio [HR]log10 decrease = 0.91, 95% CI = 0.84 to 0.98, P = .01) and the UK Biobank (HRSD decrease = 0.93, 95% CI = 0.86 to 0.99, P = .03). In gene-set enrichment analysis of differential gene expression in 445 colon tissue samples, ANGPTL4 loss-of-function down-regulated several cancer-related biological pathways (PFDR < .05), including those involved in cellular proliferation, epithelial-to-mesenchymal transition, and bile acid metabolism. In analysis of 465 colon cancer patients, lower ANGPTL4 tumor expression was associated with reduced colorectal cancer-specific mortality risk (HRlog2 decrease = 0.66, 95% CI = 0.50 to 0.87, P = 2.92 × 10−3). Conclusions: Our integrative proteogenomic and observational analyses suggest a potential protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk. These findings support further evaluation of ANGPTL4 as a therapeutic target for colorectal cancer prevention.
- 13 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1836-1847
Open AccessProteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention
Background: The role of lipid-perturbing medications in cancer risk is unclear. Methods: We employed cis-Mendelian randomization and colocalization to evaluate the role of 5 lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, and PCSK9) in risk of 5 cancers (breast, colorectal, head and neck, ovarian, and prostate). We triangulated findings using pre-diagnostic protein measures in prospective analyses in EPIC (977 colorectal cancer cases, 4080 sub-cohort members) and the UK Biobank (860 colorectal cancer cases, 50 177 controls). To gain mechanistic insight into the role of ANGPTL4 in carcinogenesis, we examined the impact of the ANGPTL4 p. E40K loss-of-function variant on differential gene expression in normal colon tissue in BarcUVa-Seq. Finally, we evaluated the association of colon tumor ANGPTL4 expression with cancer-specific mortality in TCGA. Results: In analysis of 78 473 cases and 107 143 controls, genetically proxied circulating ANGPTL4 inhibition was associated with reduced colorectal cancer risk (ORSD decrease = 0.76, 95% confidence interval [CI] = 0.66 to 0.89, P = 5.52 × 10−4, PPcolocalization = 0.83). This association was replicated using pre-diagnostic circulating ANGPTL4 concentrations in EPIC (hazard ratio [HR]log10 decrease = 0.91, 95% CI = 0.84 to 0.98, P = .01) and the UK Biobank (HRSD decrease = 0.93, 95% CI = 0.86 to 0.99, P = .03). In gene-set enrichment analysis of differential gene expression in 445 colon tissue samples, ANGPTL4 loss-of-function down-regulated several cancer-related biological pathways (PFDR < .05), including those involved in cellular proliferation, epithelial-to-mesenchymal transition, and bile acid metabolism. In analysis of 465 colon cancer patients, lower ANGPTL4 tumor expression was associated with reduced colorectal cancer-specific mortality risk (HRlog2 decrease = 0.66, 95% CI = 0.50 to 0.87, P = 2.92 × 10−3). Conclusions: Our integrative proteogenomic and observational analyses suggest a potential protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk. These findings support further evaluation of ANGPTL4 as a therapeutic target for colorectal cancer prevention.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
ST12: STOBE-MR checklist. from Is Metabolic Syndrome a Risk Factor for Skin Cancer? A UK Biobank Observational and Two-Sample Mendelian Randomization Study
Supplementary Table 12 shows the STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessST12: STOBE-MR checklist. from Is Metabolic Syndrome a Risk Factor for Skin Cancer? A UK Biobank Observational and Two-Sample Mendelian Randomization Study
Supplementary Table 12 shows the STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Data from Is Metabolic Syndrome a Risk Factor for Skin Cancer? A UK Biobank Observational and Two-Sample Mendelian Randomization Study
Background:Skin cancers are the third most common cancer worldwide, with incidence increasing. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities strongly associated with the development of cardiovascular disease. More than one in five individuals have MetS, and it is linked with at least 14 different cancers. This study aimed to investigate whether MetS is a risk factor for skin cancer.Methods:A prospective cohort study was conducted in the UK Biobank. The association between MetS and skin cancer was investigated using multivariable Poisson regression. To investigate causality, a two-sample Mendelian randomization (MR) study was conducted using summary-level genome-wide association study data from the UK Biobank (MetS) and FinnGen (skin cancer).Results:A total of 467,919 participants were included; 26.7% had MetS. Follow-up was for up to 10.8 years. MetS showed a moderately sized protective effect on basal-cell carcinoma, whereas the effect for squamous cell carcinoma and malignant melanoma crossed the null. Overall, MR found there was some weak evidence for increased odds of skin cancer in those with MetS [OR = 1.07 (95% confidence interval: 1.01, 1.14)].Conclusions:The observational study identifies a moderately sized protective effect of MetS on basal-cell carcinoma with MR evidence suggesting a weak causal effect in the opposite direction.Impact:This study has found little-to-no effect of MetS on skin cancer despite links between MetS and at least 14 other cancers.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Is Metabolic Syndrome a Risk Factor for Skin Cancer? A UK Biobank Observational and Two-Sample Mendelian Randomization Study
Background:Skin cancers are the third most common cancer worldwide, with incidence increasing. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities strongly associated with the development of cardiovascular disease. More than one in five individuals have MetS, and it is linked with at least 14 different cancers. This study aimed to investigate whether MetS is a risk factor for skin cancer.Methods:A prospective cohort study was conducted in the UK Biobank. The association between MetS and skin cancer was investigated using multivariable Poisson regression. To investigate causality, a two-sample Mendelian randomization (MR) study was conducted using summary-level genome-wide association study data from the UK Biobank (MetS) and FinnGen (skin cancer).Results:A total of 467,919 participants were included; 26.7% had MetS. Follow-up was for up to 10.8 years. MetS showed a moderately sized protective effect on basal-cell carcinoma, whereas the effect for squamous cell carcinoma and malignant melanoma crossed the null. Overall, MR found there was some weak evidence for increased odds of skin cancer in those with MetS [OR = 1.07 (95% confidence interval: 1.01, 1.14)].Conclusions:The observational study identifies a moderately sized protective effect of MetS on basal-cell carcinoma with MR evidence suggesting a weak causal effect in the opposite direction.Impact:This study has found little-to-no effect of MetS on skin cancer despite links between MetS and at least 14 other cancers.